Kaiser Permanente GLP-1 Prior Authorization & Coverage Guide: What Kaiser Covers for Weight Loss After the January 2025 Change (2026)

If you have Kaiser Permanente and you're hoping to get a GLP-1 like Wegovy or Zepbound covered for weight loss alone, the short answer is usually no. As of January 2025, Kaiser stopped covering GLP-1 medications when they are prescribed for the sole purpose of weight loss under base coverage. GLP-1s prescribed for a disease indication — most commonly type 2 diabetes (Ozempic, Mounjaro, Trulicity) — remain covered. Where weight-management coverage still exists (certain employer, exchange, and FEHB plans, and some regions), Wegovy, Saxenda, and Zepbound require prior authorization with strict BMI, step-therapy, lifestyle-program, and reauthorization criteria.

Bottom line: what Kaiser covers (and doesn't)

• Diabetes GLP-1s remain covered. Ozempic, Mounjaro, and Trulicity, when prescribed for type 2 diabetes, continue to be covered.
• Weight-loss-only GLP-1s are the restricted ones. Wegovy, Zepbound, and Saxenda are the obesity medications that, as of January 2025, are no longer covered for the sole purpose of weight loss under base coverage.
• Where weight-management coverage remains, Wegovy, Saxenda, and Zepbound require prior authorization on a dedicated Weight Management Agents form — initial approval 6 months, continuation 6 months.
• BMI gate: ≥30, OR 27–<30 with a weight-related comorbidity.
• Regional variation is significant. California base commercial and individual/family plans dropped weight-loss-only GLP-1 coverage on 1/1/2025, and Medicare Advantage cannot cover weight-loss GLP-1s by federal law.

Prior-authorization criteria

On the plans that still carry weight-management coverage, the prior-authorization criteria for Wegovy, Saxenda, and Zepbound are strict. The detailed criteria below are drawn from Kaiser's Weight Management Agents form; the core requirements are:

• Prior authorization is required on a dedicated Weight Management Agents form, with an initial approval of 6 months and a continuation approval of 6 months.
• BMI gate: BMI ≥30, OR BMI 27–<30 with a weight-related comorbidity.
• Step therapy: documented failure of phentermine, Qsymia, AND Contrave. Zepbound and Saxenda additionally require a prior Wegovy trial.
• Reauthorization: at least 5% weight loss in the prior 3 months to continue.
• Zepbound washout: Zepbound requires a 16-week washout off other GLP-1s first.
• Mandatory lifestyle-program enrollment: Kaiser's Diabetes Prevention Program (KP DPP), Healthy Weight by Design, or a partner program such as WeightWatchers, Noom, or Jenny Craig.

The 2025 weight-loss coverage change

Kaiser announced the change in a member flyer distributed in October 2024. The flyer draws a clear line between disease-management use and weight-loss-only use:

“Weight loss medications, including GLP-1s and other anti-obesity medications, continue to be covered when prescribed as part of a disease management program for conditions such as diabetes.”

“Starting in January 2025, these medications will no longer be covered for the sole purpose of weight loss.”

Both statements are verbatim from the Kaiser Permanente member flyer, October 2024. In practical terms, this means a member with type 2 diabetes can still get a covered GLP-1, while a member seeking the same drug purely to lose weight will, on base coverage, receive a denial.

How to appeal a Kaiser denial

Kaiser is an integrated HMO, so prior authorization and appeals are handled internally by Kaiser itself — not by a third-party pharmacy benefit manager. If your GLP-1 is denied, the escalation path generally runs:

1. File an internal appeal or grievance with Kaiser Member Services per the terms of your Evidence of Coverage (EOC) — commonly around 30 days to file.
2. Request an expedited appeal if your case is urgent.
3. Pursue external independent review. In California, this is an Independent Medical Review (IMR) through the Department of Managed Health Care (DMHC), which is free to members.
4. Medicare Advantage members escalate instead to the federal Independent Review Entity (IRE).

One honest caveat: the detailed PA criteria above are drawn from Kaiser Mid-Atlantic forms. Other Kaiser regions use their own forms with broadly similar — but not identical — criteria. Always confirm your own region's formulary and the exact requirements on your plan before filing.

Further reading

• Cheapest GLP-1 without insurance: buyer's guide
• Best semaglutide providers